[Treatment strategy for B cell precursor acute lymphoblastic leukemia in children]

Over the last 60 years, treatment outcomes for pediatric B cell precursor acute lymphoblastic leukemia have improved dramatically, resulting in long-term survival in approximately 90% of cases. These advancements are the results findings of Biological studies, their acceptance as prognostic factors for treatment responses, including MRD, and the accumulation of clinical trials including many randomized controlled trials. Further improvements in the cure rate and reduction of short-term and long-term complications will be issued in the future. To address such issues, new drugs such as immunotherapy and molecular targeted therapy, as well as more precise stratification, are required, and it is expected that progress will be made by promoting clinical trials in the future.